Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Papulopustular Rosacea
Interventions: Azelaic acid foam, 15% (BAY39-6251), Vehicle foam; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 961 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 49
States / cities: Birmingham, Alabama • Fremont, California • Los Angeles, California + 41 more

Conditions: Papulopustular Rosacea (PPR)
Interventions: CD5024, Azelaic acid 15% Gel; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 40
States / cities: Birmingham, Alabama • Rogers, Arkansas • Los Angeles, California + 36 more

Conditions: Non-small Cell Lung Cancer, Melanoma
Interventions: IMM60, Pembrolizumab; Drug
Lead sponsor: iOx Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 5
States / cities: Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more

Conditions: Atopic Dermatitis
Interventions: emollient (Cetaphil cream); Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: Up to 1 Month
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Advanced, Metastatic Breast Cancer
Interventions: Ribociclib, Letrozole, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 668 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 73
States / cities: Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more

Conditions: Molluscum Contagiosum
Interventions: SB206 12%, Placebo; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 35
States / cities: Mobile, Alabama • Glendale, Arizona • Little Rock, Arkansas + 32 more

Conditions: Diabetic Foot Infection, Diabetic Foot
Interventions: Topical Pravibismane, Standard of Care; Drug · Other
Lead sponsor: Microbion Corporation; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 7
States / cities: Fresno, California • Dallas, Texas • McAllen, Texas + 1 more

Conditions: Ingrown Nail
Interventions: oxidized regenerated cellulose collagen-silver, topical silver sulfadiazine cream; Device · Drug
Lead sponsor: Rosalind Franklin University of Medicine and Science; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: North Chicago, Illinois • Roanoke, Virginia

Conditions: Melanoma
Interventions: recMAGE-A3 + AS15 ASCI; Biological
Lead sponsor: Craig L Slingluff, Jr; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Idiopathic Thrombocytopenic Purpura
Interventions: Romiplostim; Biological
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 8
States / cities: Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more

Conditions: Arthritis, Rheumatoid
Interventions: Apremilast, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, CDH
Interventions: Trinity CoC Total Hip System, Trinity Ceramic-on-Poly THR; Device
Lead sponsor: Corin; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 9
States / cities: Little Rock, Arkansas • Parker, Colorado • Hartford, Connecticut + 5 more

Conditions: Mucopolysaccharidosis I
Interventions: No Intervention; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: Not listed
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Breast Cancer
Interventions: 99m Tc-TM; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Papulopustular Rosacea
Interventions: Rifaximin, Placebo; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 38
States / cities: Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more

Conditions: Psoriasis
Interventions: Secukinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Breast Neoplasms
Interventions: Blood draw; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 2
States / cities: St Louis, Missouri • Charleston, South Carolina

Conditions: Psoriasis
Interventions: Corticosteroid, Placebo, LCD; Drug · Other
Lead sponsor: NeoStrata Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Primary Immune Thrombocytopenia
Interventions: Rozanolixizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Verruca Vulgaris, Warts, Common Wart
Interventions: VDMN-21 Patch Low Dose, VDMN-21 Patch High Dose, Vehicle Patch; Drug
Lead sponsor: Veradermics, Inc.; Industry
Eligibility: 9 Years to 65 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 16
States / cities: Fort Smith, Arkansas • San Diego, California • Plainfield, Indiana + 13 more

Conditions: Lupus Nephritis, Proteinuria, Hematuria
Interventions: Velcade; Drug
Lead sponsor: The Rogosin Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Neuropathic Limb, Elevated Temperature, Shear Pressure, Increased Temperatures
Interventions: TempTouchRM, Offloading; Device
Lead sponsor: Diabetica Solutions Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anxiety, Supportive Care in Cancer, Depression
Interventions: Living Well Program; Device
Lead sponsor: Scott A. Irwin, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Epidermolysis Bullosa
Interventions: Cellutome Epidermal Harvesting System; Device
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

Phase 3 Papulopustular Rosacea Study

IMM60 and Pembrolizumab in Melanoma and NSCLC

An Open-Label Study Investigating the Effects of Early Skin Barrier Protection on the Development of Atopic Dermatitis

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Multi-center Study to Assess Safety, Tolerability and Efficacy of Topical Pravibismane in Moderate DFI Patients

Topical Collagen-Silver Versus Standard Care Following Removal of Ingrown Nails

Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI

Interventional Study in Adults With Immune Thrombocytopenia Purpura (ITP) Receiving Romiplostim

Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARA

Trinity™ BIOLOX Delta™ CoC THR Multi-center Study

Long Term Follow-Up for RGX-111

Evaluating the Ability of 99mTc-Tilmanocept to Identify Clipped Nodes in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Sentinel Lymph Node Dissection

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis

A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients

Combining Topical Corticosteroid and LCD Treatment for Localized Plaque Psoriasis

A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

Velcade for Proliferative Lupus Nephritis

Novel Home Care Device for High-Risk Diabetic Patients

Living Well Program: Impact on Healthcare Costs and Clinical Outcomes in Breast Cancer Care

Study of Cellutome System for Treatment of Individual Lesions in EB Pts